Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 59Gynecologic 51Thoracic 32Gastrointestinal 29Genitourinary 7Head & Neck 6Sarcoma 4Dermatologic 4CNS 2Plasma cell 1Other solid neoplasm 1Other 1Lymphoid 1Endocrine 1

Conditions

Urinary Bladder Neoplasms 1Pancreatic Neoplasms 1Neoplasms 1Lymphoma 1Lung Neoplasms 1

Interventions

Rituximab 530Cyclophosphamide 425Vincristine 219Doxorubicin 192fludarabine phosphate 177Etoposide 167Prednisone 166fludarabine 162Methotrexate 162Cytarabine 157Filgrastim 125Dexamethasone 123Lenalidomide 121Granulocyte Colony-Stimulating Factor 116Whole-Body Irradiation 107Mycophenolic Acid 99ibrutinib 97Bendamustine Hydrochloride 91Tacrolimus 88Melphalan 85Calcium Dobesilate 82Peripheral Blood Stem Cell Transplantation 80Bortezomib 80Busulfan 78obinutuzumab 64ofatumumab 59Radiotherapy 57Cyclosporine 57Antilymphocyte Serum 55Brentuximab Vedotin 54

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Taxes × Lymphoid × Clear all
NCT03884556 2025-07-02

TTX-030 Single Agent and in Combination With Immunotherapy or Chemotherapy for Patients With Advanced Cancers

Trishula Therapeutics, Inc.

Phase 1 Completed
56 enrolled 19 charts
GastrointestinalGenitourinaryLymphoidThoracic

Urinary Bladder Neoplasms, Lung Neoplasms, Lymphoma, Neoplasms, Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡